Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 31
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 31

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness
Readiness leaderLyell Immunopharma · 32
Strongest available pathAnaptysBio · +205.8%
Widest latest marginAnaptysBio · -5.6%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1LYEL · Nasdaq

Lyell Immunopharma

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2018San Francisco, California$355.9M market cap
View full Companies Radar profile
32Cautious
Snapshot price$14.53as of page date
Monthly-close return-95.1%five-year window
FY2025 revenue$0.00BLyell Immunopharma, Inc.
Net margin-762355.6%FY2025
P/E snapshot-2.3xone ratio, not a verdict
Prism attention21.9%share across these five
Filing track recordRevenue, USD billions
-99.7%
$0$0.0B$0.1B$0.1BFY2021: $0.011BFY2022: $0.085BFY2023: $0.000BFY2024: $0.000BFY2025: $0.000B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -75.9%
52-week position11% through range
$10.76$45.00
News mentions591
Community mentions5partial coverage
U.S.-scope patents163
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal32/100
Management stability90/100
Market position5/100
Capital-event signal25/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2UNCY · Nasdaq

Unicycive

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2016San Francisco, California$138.3M market cap
View full Companies Radar profile
32Cautious
Snapshot price$5.05as of page date
Monthly-close return-82.2%five-year window
FY2024 revenue$0.00BUnicycive Therapeutics, Inc.
Net margin-5441.3%FY2024
P/E snapshot3.6xone ratio, not a verdict
Prism attention8.3%share across these five
Filing track recordRevenue, USD billions
-29.0%
$0$0.0B$0.0B$0.0BFY2022: $0.001BFY2023: $0.001BFY2024: $0.001B202220232024
FY2022–FY2024 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -15.8%
52-week position27% through range
$3.71$8.74
News mentions225
Community mentions0partial coverage
U.S.-scope patents45
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal47/100
Management stability70/100
Market position0/100
Capital-event signal22/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3ANAB · Nasdaq

AnaptysBio

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2005San Diego, California$1.64B market cap
View full Companies Radar profile
31Cautious
Snapshot price$55.28as of page date
Monthly-close return+205.8%five-year window
FY2025 revenue$0.23BANAPTYSBIO, INC
Net margin-5.6%FY2025
P/E snapshot12.7xone ratio, not a verdict
Prism attention37.0%share across these five
Filing track recordRevenue, USD billions
+271.4%
$0$0.1B$0.2B$0.2BFY2021: $0.063BFY2022: $0.010BFY2023: $0.017BFY2024: $0.091BFY2025: $0.235B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 38.8%
52-week position72% through range
$11.40$72.36
News mentions1.0K
Community mentions11partial coverage
U.S.-scope patents326
Prism Insights

What sits behind the readiness signal

Observed risk 7/100higher means more observed risk
Earnings signal34/100
Management stability90/100
Market position0/100
Capital-event signal39/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 2 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4ERNA · Nasdaq

Brooklyn ImmunoTherapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2018New York City$5.1M market cap
View full Companies Radar profile
31Cautious
Snapshot price$4.35as of page date
Monthly-close return-100.0%five-year window
FY2025 revenue$0.00BErnexa Therapeutics Inc.
Net margin-2419.9%FY2025
Prism attention4.5%share across these five
Filing track recordRevenue, USD billions
-97.1%
$0$0.0B$0.0B$0.0BFY2019: $0.020BFY2020: $0.006BFY2023: $0.000BFY2024: $0.001BFY2025: $0.001B20192020202320242025
FY2019–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2023, FY2024, FY2025 · CAGR -58.6%
52-week position2% through range
$3.18$71.50
News mentions121
Community mentions0partial coverage
U.S.-scope patents11
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal26/100
Management stability90/100
Market position11/100
Capital-event signal25/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 8 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5CVSI · OTC

CV Sciences

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2010Las Vegas, Nevada$4.5M market cap
View full Companies Radar profile
31Cautious
Snapshot price$0.02as of page date
Monthly-close return-91.7%five-year window
FY2025 revenue$0.01BCV Sciences, Inc.
Net margin-6.9%FY2025
Prism attention28.3%share across these five
Filing track recordRevenue, USD billions
-31.2%
$0$0.0B$0.0B$0.0BFY2021: $0.020BFY2022: $0.016BFY2023: $0.016BFY2024: $0.016BFY2025: $0.014B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -8.9%
52-week position11% through range
$0.01$0.10
News mentions766
Community mentions0partial coverage
U.S.-scope patents21
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal34/100
Management stability90/100
Market position26/100
Capital-event signal0/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

AnaptysBio
+205.8%
Unicycive
-82.2%
CV Sciences
-91.7%
Lyell Immunopharma
-95.1%
Brooklyn ImmunoTherapeutics
-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

AnaptysBio
$0.23B
CV Sciences
$0.01B
Unicycive
$0.00B
Brooklyn ImmunoTherapeutics
$0.00B
Lyell Immunopharma
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

AnaptysBio
-5.6%
CV Sciences
-6.9%
Brooklyn ImmunoTherapeutics
-2419.9%
Unicycive
-5441.3%
Lyell Immunopharma
-762355.6%

Prism news attention

Normalized share across these five names; attention is not quality.

AnaptysBio
37.0%
CV Sciences
28.3%
Lyell Immunopharma
21.9%
Unicycive
8.3%
Brooklyn ImmunoTherapeutics
4.5%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

AnaptysBio leads the conversation

It holds 37.0% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.23B.

Price path

AnaptysBio leads the available price paths

Its monthly-close return is +205.8% for the five-year window. At the other end, Brooklyn ImmunoTherapeutics is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

AnaptysBio has the widest latest margin

Its FY2025 net margin is -5.6%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Lyell Immunopharma shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -2.3x while its five-year window price return is -95.1%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · ANAB

AnaptysBio

1,001available Prism news records

Prism top themes

Price action & investor response
103
Legal, arbitration & regulatory
53
Leadership & governance
32
Earnings & financial performance
29
Capital allocation & transactions
22

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+7.2%239 latest 12m vs 223 prior 12m
2024-01: 6 mentions2024-02: 8 mentions2024-03: 10 mentions2024-04: 6 mentions2024-05: 11 mentions2024-06: 10 mentions2024-07: 7 mentions2024-08: 28 mentions2024-09: 3 mentions2024-10: 10 mentions2024-11: 17 mentions2024-12: 17 mentions2025-01: 6 mentions2025-02: 79 mentions2025-03: 19 mentions2025-04: 1 mentions2025-05: 22 mentions2025-06: 14 mentions2025-07: 3 mentions2025-08: 5 mentions2025-09: 12 mentions2025-10: 8 mentions2025-11: 33 mentions2025-12: 15 mentions2026-01: 25 mentions2026-02: 13 mentions2026-03: 30 mentions2026-04: 54 mentions2026-05: 40 mentions2026-06: 1 mentions2024-012026-06

Machine-classified coverage tone

84.5% positive-2.6 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 32stock price 24share price 19adc therapeutics 10phase ii trial 9startup valuation 8phase iii trial 8immunotherapy 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-11–2026-06-02 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

LYEL

Lyell Immunopharma

through 2025-08-13
Earnings releases 4M&A 2Business contracts 1Leadership changes 1
  1. Earnings releases

    Lyell reported a net loss of $42.7 million for the second quarter ended June 30, 2025.

  2. M&A

    Lyell Immunopharma, a leader in next-generation CAR T-cell therapies, has acquired ImmPACT Bio to enhance its clinical pipeline with the promising IMPT-314 product candidate.

  3. Business contracts

    On Sept. 11, Cel­lares announced it had partnered with Lyell Immunopharma to develop its pre‑clinical CAR T‑cell therapy for solid tumours.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

UNCY

Unicycive

through 2025-04-06
Earnings releases 3
  1. Earnings releases

    HC Wainwright analyst E. Arce now forecasts that the company will post earnings of ($0.08) per share for the quarter, down from their previous estimate of ($0.07).

  2. Earnings releases

    Net loss attributable to common stockholders for the three months ended March 31, 2024 was $21.2 million, or $0.61 per share of common stock.

  3. Earnings releases

    Licensing revenues were $0.7 million for the quarter ended March 31, 2023 due to a licensing agreement executed in February 2023.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ANAB

AnaptysBio

through 2026-04-27
Earnings releases 9Listing / IPO 3Lawsuits 2Business contracts 1Company announcements 1
  1. Lawsuits

    TESARO, a subsidiary of GSK plc (LSE/NYSE: GSK), has announced an update regarding its ongoing legal dispute with AnaptysBio, Inc. The Delaware Chancery Court granted AnaptysBio’s motion to dismiss TESARO’s claim for anticipatory breach.

  2. Earnings releases

    Net loss was $38.6 million and $78.0 million for the three and six months ended June 30, 2025, or a net loss per share of $1.34 and $2.62.

  3. Company announcements

    On June 3, 2025, AnaptysBio announced positive results from its Phase 2b RENOIR clinical trial for rosnilimab, a treatment targeting PD-1+ T cells in patients with moderate-to-severe rheumatoid arthritis.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ERNA

Brooklyn ImmunoTherapeutics

through 2026-09-01
Leadership changes 8M&A 8Earnings releases 3Company announcements 2Funding Rounds 1
  1. Leadership changes

    Prism's available event log records 8 leadership changes for Brooklyn ImmunoTherapeutics.

  2. M&A

    Prism's available event log records 8 m&a for Brooklyn ImmunoTherapeutics.

  3. Earnings releases

    Prism's available event log records 3 earnings releases for Brooklyn ImmunoTherapeutics.

Cached Prism company-event evidence fallback; totals describe available coverage and the displayed highlights prefer filing-backed earnings rows.

CVSI

CV Sciences

through 2026-03-28
Earnings releases 21Business contracts 2M&A 2
  1. Earnings releases

    In the fourth quarter, revenue was $3.3 million versus $3.9 million in the year-ago quarter and was consistent with the third quarter of 2025.

  2. Business contracts

    Las Vegas-based CV Sciences (CVSI) announced Wednesday that its CBD oil will be sold in 945 Kroger-owned stores spanning 17 U.S. states.

  3. M&A

    CV Sciences, Inc. (OTCQB:CVSI), a prominent consumer wellness company focusing on hemp extracts and other science-backed natural ingredients, has completed the acquisition of Elevated Softgels, LLC.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 151–158. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with AnaptysBio and AnaptysBio

AnaptysBio has the largest displayed latest revenue at $0.23B; AnaptysBio has the widest displayed latest margin at -5.6%.

Open AnaptysBio in Companies Radar
Comparisons
Anomalies

CV Sciences has the widest attention-readiness rank gap

It ranks #2 by measured news attention (28.3%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open CV Sciences in Companies Radar

AnaptysBio shows a price-operating divergence to inspect

Its displayed filing-revenue change is +271.4% while its available monthly-close return is +205.8%. This is the basket's largest numerical spread; the measures use different units and windows and are not directly equivalent.

Open AnaptysBio in Companies Radar
Explanations

Attention measures coverage volume, not quality

AnaptysBio's 37.0% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open AnaptysBio in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Lyell Immunopharma's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 32/100 score.

Open Lyell Immunopharma in Companies Radar

Stress-test the largest divergence before forming a view

Compare AnaptysBio's profile with AnaptysBio's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open AnaptysBio in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon